Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan.

Yasuhiro AokiTomohisa SujinoTakaaki KawaguchiShinya SugimotoFumie ShimadaYusuke YoshimatsuHiroki KiyoharaKosaku NankiYohei MikamiKaoru TakabayashiNaoki HosoeHaruhiko OgataYasushi IwaoTakanori Kanai

Published in: Crohn's & colitis 360 (2022)

The response rate for Japanese UC patients is similar to previous reports based on American and European UC patients. There was no significant difference between the ustekinumab monotherapy group and the ustekinumab and IM combination group in the real world.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
randomized controlled trial
systematic review
ulcerative colitis
emergency department
patient reported outcomes
patient reported
study protocol
double blind